FDA backs the benefits of adopting continuous manufacturing, a strategy which has accelerated approval and launch timelines, and its Emerging Technology Program could be a helpful tool.
Adam C. Fisher, PhD
Advertisement
Adam C. Fisher, Phd, is Director of Science Staff, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, FDA.
Articles by Adam C. Fisher, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement